Search

Flutamide

An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Chromous sulfate

PPI-2458

Clinical development with previous fumagillin derivatives has been limited by their toxicity profile.

Vanoxerine

Although several studies have suggested that the profile of vanoxerine is safer than that of cocaine,[A19824,A248550] other studies have found that vanoxerine has at least moderate potential to be abused by

DDP-200

DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

XTL-001

XTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected

BMS-564929

So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.

Zilebesiran

Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care

AM336

Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.

Tanespimycin

Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90).